Join to View Full Profile
6565 Fannin StHouston, TX 77030
Phone+1 714-441-1450
Fax+1 713-790-8750
Dr. Hill is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- LaQuisa Hill, MD is an Oncologist based in Houston, TX, with a subspecialty in Hematologic Oncology and Stem Cell Transplantation/Cellular Therapy. She received her education from the University of Texas Medical Branch School of Medicine and furthered her training with an Internal Medicine Residency at Vanderbilt University Medical Center and a Hematology and Oncology Fellowship at University of Texas MD Anderson Cancer Center. Dr. Hill has expertise in treating conditions like AML, ALL, myelodysplasia, myelofibrosis, and multiple myeloma. She has published multiple papers in reputable journals and is involved in clinical trials, focusing on cell therapy for refractory hematologic malignancies; specifically T-cell driven diseases. In 2011, she was inducted into the Alpha Omega Alpha Honor Medical Society. She is an active member of ASH, ASTCT, ASGCT, and ISCT.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Vanderbilt University Medical CenterResidency, Internal Medicine, 2011 - 2014
University of Texas Medical Branch School of MedicineClass of 2011
Certifications & Licensure
TX State Medical License 2015 - 2027
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Clinical Trials
- Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells Start of enrollment: 2021 Aug 02
- Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen Start of enrollment: 2020 Jul 09
- Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease) Start of enrollment: 2021 Feb 12
Publications & Presentations
PubMed
- Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial.Asad Bashey, Brent R Logan, LaQuisa C Hill, Heather J Symons, Nosha Farhadfar
Blood Advances. 2026-06-05 - Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial.Joseph Pidala, Brent Logan, Stephanie J Lee, Bronwen E Shaw, Steven Devine
Transplantation and Cellular Therapy. 2026-06-01 - Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study.Lori Muffly, Noelle V Frey, Gregory W Roloff, Jae H Park, Bhagirathbhai Dholaria
Blood. 2026-05-19
Press Mentions
CAR T Cells Produce Complete Responses in T-cell MalignanciesJanuary 7th, 2020
Stand up to Cancer Dream Team Tackles T-cell Lymphoma, Focused on CAR-Based StrategiesJanuary 28th, 2019- CAR T Cell Therapy for T Cell Lymphoma Shows Promise in Phase I TrialJanuary 6th, 2024
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
